Life Sciences

  • July 14, 2026

    States Will Get $18M From 23andMe Ch. 11 For Data Breach

    A week after a bankruptcy court approved a $46.75 million settlement between the DNA testing company 23andMe and data breach claimants, a coalition of more than 40 states announced Tuesday that they would share in an additional $18 million to resolve claims of unreasonable security practices.

  • July 14, 2026

    Pharma Cos. Clash In Del. Chancery Over Dental Drug License

    Ventis Pharma Inc. has sued Balanced Pharma Inc. in the Delaware Chancery Court, accusing its licensee of failing to make commercially reasonable efforts to develop and market a licensed dental anesthetic product and seeking a declaration that the companies' exclusive licensing agreement has been terminated.

  • July 13, 2026

    Albertsons, Safeway Face Trial Over Wash.'s Opioid Epidemic

    Albertsons and Safeway ignored signs of problematic opioid prescriptions in Washington for years, an attorney for the state told a Seattle judge Monday during opening statements in a bench trial over allegations that the pharmacy chains failed to prevent the diversion of opioids that fueled the state's long-running overdose crisis.

  • July 13, 2026

    2nd Circ. Says Tylenol Maker Must Face Autism, ADHD Suits

    The Second Circuit said Monday that a lower court had wrongly excluded plaintiffs experts from testifying about an alleged relationship between using Tylenol during pregnancy and autism spectrum disorder and attention-deficit/hyperactivity disorder, although the panel cautioned that the decision was not political or scientific.

  • July 13, 2026

    FTC Secures $12M Settlement Over Edwards-JC Medical Deal

    California-based Edwards Lifesciences and Singapore's Genesis Medtech agreed to pay a combined $12 million to settle claims from the Federal Trade Commission that Edwards attempted to evade the Hart-Scott-Rodino notification and waiting period when it acquired medical device maker JC Medical from Genesis in 2024.

  • July 13, 2026

    CVS Toddler Wipes Mislabeled As Hypoallergenic, Suit Says

    CVS customers hit the pharmacy retail giant with a proposed false advertising class action in California federal court alleging that its "Ultra-Soft Toddler Cleansing Wipes" are deceptively labeled as being hypoallergenic, since they are formulated with added fragrance, a cosmetic allergen that serves no functional skin care purpose.

  • July 13, 2026

    7th Circ. Revives Teva Suit Over Eli Lilly Generic Drug Block

    The Seventh Circuit on Monday revived a breach-of-contract lawsuit against Eli Lilly, ruling that an earlier legal settlement under which Eli Lilly agreed not to block the approval and marketing of Teva Pharmaceuticals' generic version of its osteoporosis drug Forteo didn't necessarily expire when the underlying patents did.

  • July 13, 2026

    23andMe Bankruptcy Plan Bars Data Breach Suit In Calif.

    A Missouri bankruptcy judge has told attorneys representing California the state can no longer press its data breach lawsuit against the reorganized 23andMe, finding the state court action is barred by the company's confirmed Chapter 11 plan.

  • July 13, 2026

    Assertio Beats Investor Suit Over Drug, Merger Claims

    An Illinois federal judge Friday dismissed a proposed investor class action claiming Assertio misled shareholders about threats to sales of its arthritis drug Indocin, saying the company's public filings explicitly and repeatedly warned that the drug lacked patent protection and faced imminent generic competition at any time.

  • July 13, 2026

    Families Cite Geofence Ruling In Newborn Blood Testing Case

    A group of parents suing the state of Michigan over the way newborn blood samples are collected and stored has asked a federal judge to revive its claims by citing recently decided U.S. Supreme Court precedent over the use of bulk cellphone data by police.

  • July 13, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week handled disputes involving corporate control, post-closing competition, executive departures, arbitration awards and shareholder litigation.

  • July 13, 2026

    Health Org. Can't Halt FTC Texas Suit Over Trans Youth Care

    A D.C. federal court declined to bar the Federal Trade Commission from pursuing a consumer protection suit in Texas against the World Professional Association for Transgender Health, finding WPATH failed to show those proceedings threatened the court's injunction of a related investigation by the FTC.

  • July 10, 2026

    Thermo Fisher Looks To Block Former Exec's Move To Fortrea

    Thermo Fisher is asking a Delaware court to prevent a former executive's move to a direct competitor following its $8.875 billion acquisition of Clario in March 2026, saying the new leadership role is in violation of contractual obligations negotiated as part of the acquisition.

  • July 10, 2026

    Chemours Says NC Resident's PFAS 'Equity Action' Must Fail

    DuPont entity and spinoff Chemours Inc. has told a North Carolina federal court it shouldn't have to face a PFAS contamination suit from a state resident, saying in her early-stage court filings, she's conceded that her "equity action" is doomed to fail.

  • July 10, 2026

    DOJ Appeals Order Shielding Trans Youth Medical Records

    The U.S. Department of Justice asked the Ninth Circuit to review a California federal court's order blocking the government from trying to identify individuals who received gender-affirming care from a Stanford Medicine hospital as minors.

  • July 10, 2026

    Medical Device Co. Hit With Action Over Data Breach

    Pennsylvania-based medical device company AdaptHealth Corp. is facing a putative class action in federal court alleging the company was liable for a data breach last month that exposed the sensitive information of its customers.

  • July 10, 2026

    Fed. Circ. Won't Rethink Corcept Patent Loss In Teva Case

    Corcept Therapeutics Inc. lost its bid Friday to have the full Federal Circuit look at a panel's refusal to revive its suit accusing Teva Pharmaceuticals USA Inc. of patent infringement over its production of a generic version of the drug Korlym.

  • July 10, 2026

    Boston Scientific Top Brass Sued Over Pacemaker Recall

    A Boston Scientific Corp. shareholder has filed a derivative lawsuit against the company's current and former directors and top executives, claiming they ignored early signs of an issue with the company's pacemakers that led to a recall and has been connected to four deaths.

  • July 10, 2026

    Ex-Biomedical Worker Axed For Not Altering Data, Suit Says

    A former regulatory affairs specialist for biomedical company Vitara has alleged in New Jersey state court that she was fired in retaliation for refusing to manipulate data in the company's bid to perform the first human trial of its technology aimed at helping premature newborns.

  • July 10, 2026

    4 Firms Advise On $3.4B Apollo, Bayer Contraceptives Deal

    Apollo Global Management has agreed to pay €3 billion ($3.4 billion) for a minority stake in Bayer's long-acting reversible contraceptive business, according to a joint announcement Friday. 

  • July 09, 2026

    NY AG Says 3M, DuPont Hid PFAS Risks For Years

    The New York attorney general on Thursday sued 3M, DuPont and other major chemical manufacturers in state court alleging that for decades they failed to warn the public about the health risks of forever chemicals in consumer goods like cosmetics and food packaging.

  • July 09, 2026

    VSL Reaches $20M Deal Resolving Knockoff Probiotic Claims

    VSL Pharmaceuticals Inc., Sigma-Tau Pharmaceuticals Inc. and Alfasigma USA Inc. have reached a $20 million settlement with customers who bought a knockoff version of a proprietary probiotic formula for gastrointestinal ailments, according to an order preliminarily approving the deal.

  • July 09, 2026

    Judge Skeptical On Restraining Order In Affirming Care Case

    A D.C. federal judge appeared skeptical Thursday that a Federal Trade Commission case against a gender-affirming care organization must be halted while the group wages a separate case against the commission's investigation into the organization.

  • July 09, 2026

    Fed. Circ. Doubts $9M Atty Fees Without Dismissal Attempt

    A Federal Circuit panel didn't seem swayed Thursday that ChromaDex's patent infringement suit against Elysium Health had any merit, but the judges struggled to understand why Elysium never tried to dismiss a case it believed was so weak.

  • July 09, 2026

    Regeneron Cites Medtronic Ruling In Amgen Bundling Case

    Regeneron has told a Delaware federal judge there is new reason to preserve its $407 million win against Amgen over cholesterol drug bundling after a California federal judge found in an analogous case that the plaintiff need not prove the defendant had monopoly power over every item in a bundle.

Expert Analysis

  • A Midyear Look At Antiterrorism Act Jurisprudence And Policy

    Author Photo

    Plaintiffs have filed comparably fewer new actions under the Antiterrorism Act this year, though a handful of key decisions further defined the statute’s aiding-and-abetting standard and highlighted continuing risks for financial services companies, say attorneys at Skadden.

  • Opinion

    FTC's Clinical Trial Requirement Threatens Food Claim Rules

    Author Photo

    The Federal Trade Commission's general requirement for randomized controlled trials for most health-benefit claims, recently embraced by the National Advertising Review Board, lacks legal basis and endangers the existing statutory framework Congress created for marketing food and dietary supplements versus drugs, say attorneys at Keller & Heckman.

  • Drawing A Line Between Settlement Pressure And Extortion

    Author Photo

    U.S. v. Luo, pending in the U.S. District Court for the Southern District of New York, may force courts to address anew when settlement negotiations become criminal extortion, particularly in the age of easily fabricated digital evidence, says attorney Denis Kiely.

  • Series

    Founding An Autism Academy Made Me A Better Lawyer

    Author Photo

    Starting a nonprofit autism school with no building, no funding model and no guarantee that families would trust us taught me the importance of mission, patience and purpose — lessons that sharpened my practice and showed how meaningful work outside the office can make lawyers better, says Phillip Russell at Ogletree Deakins.

  • Opinion

    Rule Of Law Requires Gov't Engagement With Bar, Not Retreat

    Author Photo

    A federal agency's absence from national and local bar conferences, most recently illustrated by the U.S. Department of Justice's withdrawal from a New York City Bar Association white collar conference, disserves the bar, the government lawyers themselves and, ultimately, the administration of justice, says Muhammad Faridi at Linklaters.

  • AG Watch: Oregon's Strategic Civil Enforcement Approach

    Author Photo

    Oregon Attorney General Dan Rayfield’s recent antitrust litigation activity and proposed staffing increase are the latest in a series of structural and policy changes that signal that the state Department of Justice is taking a more aggressive approach to civil enforcement, says Keturah Taylor at Cozen O'Connor.

  • How Nasdaq's 23/5 Rule Will Alter Public Offering Strategies

    Author Photo

    The U.S. Securities and Exchange Commission's recent approval of Nasdaq's proposal to extend trading hours to 23 hours a day, five days a week, may reshape how certain public offerings are executed, particularly for confidentially marketed public offerings, say attorneys at Faegre Drinker.

  • The Paradoxical Duty To Adopt AI When You Can't Bill For It

    Author Photo

    Both billing for hours saved using artificial intelligence and preserving billable time by not adopting AI may violate rules of professional conduct, but until bar associations' ethics rules catch up to this emerging economic dilemma, firms must decide how to adjust fee structures themselves, says Ines Lassalle at Peyrot & Associates.

  • Tips For Litigating Life Sciences Investigations At The ITC

    Author Photo

    The International Trade Commission may soon become a significant battleground for life sciences companies as global intellectual property and trade disputes continue, increasing the importance of learning the ITC's unique considerations and litigation strategies, say attorneys at Crowell & Moring.

  • Ch. 15 Ruling Is A Restructuring Blueprint For Cannabis Cos.

    Author Photo

    The recent Cannabist Chapter 15 recognition order is arguably the most significant cannabis bankruptcy development in U.S. history, providing a concrete and tested road map by which such companies with foreign parent structures can access the protective machinery of U.S. bankruptcy law, say attorneys at Saul Ewing.

  • Unsecured Synthetic Royalties May Be Returning

    Author Photo

    Recent royalty monetization deals mark a notable shift in a market that had largely moved away from unsecured synthetic royalty structures after a multiyear freeze triggered by the Mallinckrodt bankruptcy decision in 2022, which exposed a legal risk inherent to the structure, says Peter Schwartz at Covington.

  • Series

    Cow Horse Makes Me A Better Lawyer

    Author Photo

    Moving an unwilling 800-pound cow while riding a horse at high speed is exhilarating, a little unhinged and, at least for me, a surprisingly effective training ground for litigation — both demand focus, preparation over rigid planning and the willingness to act despite fear, says Ashley Zitrin at Glenn Agre.

  • Protecting AI-Driven Innovation In Life Sciences IP

    Author Photo

    Recent developments, including the U.S. Patent and Trademark Office's evolving inventorship standards, and the impact of artificial intelligence on the "person of ordinary skill in the art" standard demand that life sciences companies elevate AI patent strategy to a top priority, says Sandra Haberny at Quinn Emanuel.

  • What Prop 65 Listings For Welding Fumes, Drugs Mean For Cos.

    Author Photo

    With California poised to add welding chemicals and three medications to its list of known carcinogens under Proposition 65, businesses must assess risks from nontraditional pharmaceutical dispensing, occupational and environmental exposures to welding operations, and downstream exposures from the manufacture of both types of substances, says Gregory Berlin at Alston & Bird.

  • High Court's Hikma Decision Reshapes 'Skinny Label' Suits

    Author Photo

    The U.S. Supreme Court's decision in Hikma v. Amarin marks a significant victory for generic drug manufacturers, but rather than putting an end to so-called skinny label inducement claims, it narrows and refocuses them, say attorneys at Sterne Kessler.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.